Hepsin paradox reveals unexpected complexity of metastatic process

Cell Cycle

Volumn 3, Issue 11, 2004, Pages 1394-1397

  Vasioukhin, Valeri ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cancer; Metastasis; Prostate cancer; Proteases

Indexed keywords

ALPHA CATENIN; ANDROGEN RECEPTOR; BETA4 INTEGRIN; COLLAGEN TYPE 7; CYTOKINE; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR; HEPSIN; HERMES ANTIGEN; KALININ; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P27; PROTEINASE; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR KLF6; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CHROMOSOME 8P; CHROMOSOME LOSS; ELECTRON MICROSCOPY; GLEASON SCORE; IMMUNOFLUORESCENCE; METASTASIS; NONHUMAN; PARACRINE SIGNALING; PROSTATE CANCER; REVIEW; STROMA CELL;

EID: 14644399717     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.11.1273     Document Type: Review

References (36)

1. Gao AC, Isaacs JT. The molecular basis of prostate carcinogenesis. In: Coleman WB, Tsngalis GJ, eds. The Molecular Basis of Human Cancer. Totowa: Humana Press Inc., 2002:365-83.
2. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361:955-64.
3. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91:459-77.
4. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP. Loss of nkx3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60:6111-5.
5. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the Pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91:11733-7.
6. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412:822-6.
7. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z. Molecular genetic profiling of gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001; 166:2171-7.
8. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61:5974-8.
9. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001; 61:5692-6.
10. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res 2001; 61:4683-8.
11. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M, Grone HJ. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: A gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002; 160:2169-80.
12. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 2003; 169:1316-9.
13. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004; 171:187-91.
14. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999; 13:966-77.
15. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004; 6:185-95.
16. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. Klf6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294:2563-6.
17. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the pten tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998; 4:811-5.
18. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S. Nonsense-mediated decay microarray analysis identifies mutations of ephb2 in human prostate cancer. Nat Genet 2004; 36:979-83.
19. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57:524-31.
20. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87:7762-6.
21. Jarrard DF, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze SR, Friedl A. Alterations in the P16/Prb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 2002; 185:191-9.
22. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-5.
23. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased e-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54:3929-33.
24. Gao AC, Lou W, Dong JT, Isaacs JT. Cd44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57:846-9.
25. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE. Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 1995; 146:1498-507.
26. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. Kail, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268:884-6.
27. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-Driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4:223-38.
28. Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 2004; 64:6018-25.
29. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Cristofano AD, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Dyke TV, Cordon-Cardo C, Pandolfi P. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1:E59.
30. kiP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001; 27:222-4.
31. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. Frequent inactivation of pten/mmac1 in primary prostate cancer. Cancer Res 1997; 57:4997-5000.
32. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein ezh2 is involved in progression of prostate cancer. Nature 2002; 419:624-9.
33. Karhadkar SS, Steven Bova G, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004; 431:707-12.
34. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52:6940-4.
35. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression, and androgen-dependence of prostate tumors in probasin-large t antigen transgenic mice: A model for prostate cancer. Lab Invest 1998; 78:319-33.
36. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. Hepsin inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002; 62:6812-6.